Healthcare / BiotechnologyNasdaqCM
$24.43
-0.42 (-1.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-18.6M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.5B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-87.3%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-209.8M · FCF $-6.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Net Income | $-209.8M | $-209.8M | $-21.4M | $-38.3M | $-61.6M | $-51.8M | $-34.8M | $-36.5M |
| EBITDA | $-210.8M | $-210.8M | $-21.1M | $-35.6M | $-60.7M | — | — | — |
| EPS | — | — | -18.53 | -36.08 | -60.75 | -51.25 | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | — | — | — |
| Current Ratio | 22.48 | 22.48 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-6.7M | $-6.7M | $-18.6M | $-36.9M | $-43.1M | $-52.5M | — | — |
| Returns | ||||||||
| ROE | -87.3% | -87.3% | -135.4% | -118.6% | -99.8% | -44.1% | -21.1% | 51.3% |
| Valuation | ||||||||
| P/B | 0.16 | 0.16 | 0.42 | 0.58 | 0.73 | — | — | — |
| Growth & Yield | ||||||||
| EPS Growth | — | — | 48.6% | 40.6% | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+663.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-18.53 → n/d
Residual
+663.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.